Next Day Disclosure Return

(I) AMENDMENTS TO THE SCHEME RULES OF THE 2021 SHARE AWARD SCHEME; (II) APPOINTMENT OF TRUSTEE FOR ADMINISTERING THE 2021 SHARE AWARD SCHEME; AND (III) PLAN TO SATISFY PART OF THE AWARD SHARES BY ACQUISITION OF SHARES THROUGH ON-MARKET TRANSACTIONS BY THE TRUSTEE

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2021

Next Day Disclosure Return

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2021

VOLUNTARY ANNOUNCEMENT CDE APPROVAL RECEIVED FOR CLINICAL TRIAL OF CLASS I NEW DRUG OT-202 IN CHINA

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2021

GRANT OF OPTIONS UNDER THE 2021 SHARE OPTION SCHEME ANDGRANT OF AWARDS UNDER THE 2021 SHARE AWARD SCHEM

Next Day Disclosure Return

Next Day Disclosure Return

NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS

NOTIFICATION LETTER AND REQUEST FORM TO REGISTERED SHAREHOLDERS

2021 Interim Report

VOLUNTARY ANNOUNCEMENT THE SIXTH PRODUCT OF THE COMPANY ENTERED PHASE III CLINICAL TRIAL STAGE - CDE APPROVAL RECEIVED FOR COMMENCEMENT OF A PHASE III CLINICAL TRIAL OF OT-502 (DEXYCU) IN CHINA

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2021

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON AUGUST 31, 2021

DISCLOSEABLE TRANSACTION ACQUISITION OF RIGHTS RELATING TO EMADINE AND BETOPTIC S IN CHINA

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2021

VOLUNTARY ANNOUNCEMENT OT-502 APPROVED FOR REAL WORLD STUDY IN HAINAN BOAO

COMPLETION OF ISSUE OF UNLISTED WARRANTS UNDER SPECIFIC MANDATE

NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS

NOTIFICATION LETTER AND REQUEST FORM TO REGISTERED SHAREHOLDERS

FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON TUESDAY, AUGUST 31, 2021

NOTICE OF EXTRAORDINARY GENERAL MEETING

(1) PROPOSED ADOPTION OF THE 2021 SHARE OPTION SCHEME; (2) PROPOSED GRANT OF OPTIONS UNDER THE 2021 SHARE OPTION SCHEME; (3) CONNECTED TRANSACTION INVOLVING PROPOSED GRANT OF AWARDS UNDER THE 2021 SHARE AWARD SCHEME; (4) PROPOSED GRANT OF CONNECTED GRANT SPECIFIC MANDATE AND AWARD SCHEME SPECIFIC MANDATE; AND (5) NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE OF BOARD MEETING

DELAY IN DESPATCH OF CIRCULAR IN RELATION TO PROPOSED ADOPTION OF 2021 SHARE OPTION SCHEME, PROPOSED GRANT OF OPTIONS AND PROPOSED GRANT OF AWARDS UNDER 2021 SHARE AWARD SCHEME

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2021

(Revised) Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2021

VOLUNTARY ANNOUNCEMENT MHRA APPROVAL RECEIVED FOR A PHASE III CLINICAL TRIAL OF OT-101 IN THE UNITED KINGDOM

List of Directors and their Role and Function

RE-DESIGNATION OF EXECUTIVE DIRECTORS AS NON-EXECUTIVE DIRECTORS

VOLUNTARY ANNOUNCEMENT CDE APPROVAL RECEIVED FOR A PHASE III CLINICAL TRIAL OF OT-101

VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL TRIAL OF OT-502 APPROVED IN CHINA

VOLUNTARY ANNOUNCEMENT OT-502 APPROVED FOR URGENT MEDICAL NEEDS IN HAINAN

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2021

(I) PROPOSED ADOPTION OF 2021 SHARE OPTION SCHEME AND PROPOSED GRANT OF OPTIONS; (II) ADOPTION OF 2021 SHARE AWARD SCHEME; AND(III) NON-EXEMPT CONNECTED TRANSACTION - PROPOSED GRANT OF AWARDS TO DIRECTORS

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 29, 2021

CLARIFICATION ANNOUNCEMENT IN RELATION TO PLACING OF EXISTING SHARES BY CONTROLLING SHAREHOLDERS

INSIDE INFORMATION PLACING OF EXISTING SHARES BY CONTROLLING SHAREHOLDER

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2021

NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS

NOTIFICATION LETTER AND REQUEST FORM TO REGISTERED SHAREHOLDERS

FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, JUNE 29, 2021

NOTICE OF ANNUAL GENERAL MEETING

PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED GRANTING OF SPECIFIC MANDATE TO ISSUE UNLISTED WARRANTS AND WARRANT SHARES;AND NOTICE OF ANNUAL GENERAL MEETING

VOLUNTARY ANNOUNCEMENT CLINICAL TRIAL AUTHORIZATION FOR INITIATING A PHASE III CLINICAL TRIAL OF OT-101 ACCEPTED IN UNITED KINGDOM

Next Day Disclosure Return

VOLUNTARY ANNOUNCEMENT IND APPLICATION RECEIVED FOR A PHASE III CLINICAL TRIAL OF OT-101 IN CHINA

(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2020

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2021

2020 Environmental, Social and Governance Report

NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS

NOTIFICATION LETTER AND REQUEST FORM TO REGISTERED SHAREHOLDERS

2020 Annual Report

COMPLETION OF THE TRANSACTIONS UNDER SHARE PURCHASE AGREEMENT

VOLUNTARY ANNOUNCEMENT APPROVAL FOR COMMENCEMENT OF INITIAL PEDIATRIC STUDY PLAN FOR OT-101 IN THE UNITED STATES

(I) DISCLOSEABLE TRANSACTIONS RELATING TO THE EXCLUSIVE LICENSE AGREEMENT AND THE SHARE PURCHASE AGREEMENT AND (II) THE WARRANT SUBSCRIPTION AGREEMENT WITH ALIMERA SCIENCES, INC.

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2021

VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN THE PHASE III CLINICAL TRIAL OF OT-101 IN THE UNITED STATES AND THE PLANNED REAL WORLD STUDY FOR OT-101 IN CHINA

VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR OT-401 ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020

List of Directors and their Role and Function

CHANGE OF NON-EXECUTIVE DIRECTOR

VOLUNTARY ANNOUNCEMENT INCLUSION OF THE SHARES OF THE COMPANY IN THE HONG KONG STOCK CONNECT LIST UNDER THE SHENZHEN-HONG KONG STOCK CONNECT

DATE OF BOARD MEETING

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 28 February 2021

VOLUNTARY ANNOUNCEMENT SECOND PHASE III CLINICAL TRIAL OF OT-301 APPROVED IN CHINA

VOLUNTARY ANNOUNCEMENT SELECTION OF THE SHARES OF THE COMPANY AS A CONSTITUENT OF CERTAIN INDEXES OF HANG SENG INDEXES COMPANY LIMITED

VOLUNTARY ANNOUNCEMENT IND APPROVAL RECEIVED FOR A PHASE III CLINICAL TRIAL OF OT-101 IN THE UNITED STATES

VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSING IN A PHASE III CLINICAL TRIAL OF OT-702 IN CHINA

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2021

Next Day Disclosure Return

COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

PLACING OF EXISTING SHARES TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2020

DISCLOSEABLE TRANSACTION SUBSCRIPTION OF SHARES IN EYEPOINT PHARMACEUTICALS, INC.